Mylan's merger with Pfizer's off-patent business Upjohn being monitored by Australian watchdog
MLex Summary: Mylan’s plans to combine with Pfizer’s off-patent drug business Upjohn is being monitored by Australia’s competition watchdog — a step that usually precedes the opening of an informal, public review....To view the full article, register now.
Already a subscriber? Click here to view full article